Daver, Naval

Chimeric antigen receptor T-cell therapy—assessment and management of toxicities

Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 2,438

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., McAfoos, T., Morlacchi, P., Ackroyd, J., Agip, A.-N. A., et al. (2018) · Nature Medicine

Cancer, Hypoxia, and MetabolismMitochondrial Function and Pathology

Cited by 928

The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

Williams, P., Basu, S., Garcia‐Manero, G., Hourigan, C. S., Oetjen, K. A., Cortes, J. E., Ravandi, F., Jabbour, E. J., Al‐Hamal, Z., Konopleva, M., et al. (2019) · Cancer

Acute Myeloid Leukemia ResearchCancer Immunotherapy and Biomarkers

Cited by 330

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., et al. (2023) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchPhagocytosis and Immune Regulation

Cited by 188

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Kim, K., Maiti, A., Loghavi, S., Pourebrahim, R., Kadia, T. M., Rausch, C. R., Furudate, K., Daver, N. G., Alvarado, Y., Ohanian, M., et al. (2021) · Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 161

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Daver, N., Wei, A. H., Pollyea, D. A., Fathi, A. T., Vyas, P., & DiNardo, C. D. (2020) · Blood Cancer Journal

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 159

Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia

Galloway-Peña, J. R., Shi, Y., Peterson, C. B., Sahasrabhojane, P., Gopalakrishnan, V., Brumlow, C. E., Daver, N. G., Alfayez, M., Boddu, P. C., Khan, M. A. W., et al. (2020) · Clinical Infectious Diseases

Gut microbiota and healthNeutropenia and Cancer Infections

Cited by 140

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 133

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T. M., Daver, N., Ohanian, M., Dinardo, C. D., et al. (2019) · The Lancet Haematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 120

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Boddu, P., Kantarjian, H. M., Garcia-Manero, G., Ravandi, F., Verstovsek, S., Jabbour, E., Borthakur, G., Konopleva, M., Bhalla, K. N., Daver, N., et al. (2017) · Blood Advances

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 112

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Tashakori, M., Kadia, T., Loghavi, S., Daver, N., Kanagal-Shamanna, R., Pierce, S., Sui, D., Wei, P., Khodakarami, F., Tang, Z., et al. (2022) · Blood

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 111

Magrolimab plus azacitidine vs physician’s choice for untreated TP53 -mutated acute myeloid leukemia: the ENHANCE-2 study

Zeidner, J. F., Sallman, D. A., Récher, C., Daver, N. G., Leung, A. Y. H., Hiwase, D. K., Subklewe, M., Pabst, T., Montesinos, P., Larson, R. A., et al. (2025) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 76

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation

Lontos, K., Saliba, R. M., Kanagal-Shamanna, R., Özcan, G., Ramdial, J., Chen, G., Kadia, T., Short, N. J., Daver, N. G., Kantarjian, H., et al. (2025) · Blood Advances

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation

Cited by 35

Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis

Daver, N., & Kontoyiannis, D. P. (2017) · The Lancet Oncology

Antifungal resistance and susceptibilityCancer Immunotherapy and Biomarkers

Cited by 26

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Han, L., Cavazos, A., Baran, N., Zhang, Q., Kuruvilla, V. M., Gay, J. P., Feng, N., Battula, V. L., Kantarjian, H. M., Daver, N. G., et al. (2019) · Blood

Acute Myeloid Leukemia ResearchCancer, Hypoxia, and Metabolism

Cited by 19